• 1
    Shipley WU, Zietman AL, Hanks GE, Coen JJ, Caplan RJ, Won M, et al. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with Stages T1 and T2 tumor. J Urol 1994; 152: 1799-805.
  • 2
    Hanks GE, Myers CE, Scardino PT. Prostate cancer. In: DeVitaVT, HellmanS, RosenbergSA, editors. Cancer: principals and practices of oncology. 4th edition. Philadelphia: J.B. Lippincott Co., 1993: 1073-113.
  • 3
    Scher HI, Isaacs JT, Fuks Z, Walsh PC. Prostate. In: AbeloffMD, ArmitageJO, LichterAS, NienerhuberJE, editors. Clinical oncology. New York: Churchill Livingston, 1995: 1439-72.
  • 4
    Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974; 59: 665-78.
  • 5
    Seal US, and V. A. Uro-Oncology Research Group. FSH and LH elevation after radiation for treatment of cancer of the prostate. Invest Urol 1979; 16: 278-80.
  • 6
    Grigsby PW, Perez CA. The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J Urol 1986; 135: 726-7.
  • 7
    Tomic R, Bergman B, Damber JE, Littbrand B, Lofroth PO. Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and pProlactin. J Urol 1983; 130: 287-9.
  • 8
    Iversen P, Rasmussen F, Christensen J. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol 1994; 157: 41-7.
  • 9
    Haapiainen R, Rannikko S, Alfthan O, Aldercreutz H, Finnprostate Group. Pretreatment plasma levels of testosterone and sex hormone binding globulin binding capacity in relation to clinical staging and survival in prostatic cancer patients. Prostate 1988; 12: 325-32.
  • 10
    Eriksson A, Carlstrom K. Prognostic value of serum hormone concentrations in prostatic cancer. Prostate 1988; 13: 249-56.
  • 11
    Ishikawa S, Soloway MS, Van Der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139-42.
  • 12
    Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognosis factors in patients with metastatic (Stage D2) prostate cancer. JAMA 1991; 265: 618-21.
  • 13
    Ernst DS, Hanson J, Venner PM, and Uro-Oncology Group of Northern Alberta. Analysis of prognostic factors in men with metastatic prostate cancer. J Urol 1991; 146: 372-6.
  • 14
    Mulders PFA, Dijkman GA, del Moral PF, Theeuwes GM, Debruyne FMJ, and Members of the Dutch Southeastern Urological Cooperative Group. Analysis of prognostic factors in disseminated prostatic cancer. Cancer 1990; 65: 2758-61.
  • 15
    Kreis W, Ahmann ML, Lesser M, Scott M, Caplan R, Gau T, et al. Predictive initial parameters for response of Stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Oncol 1990; 8: 870-4.
  • 16
    Matzkin H, Soloway MS, Schellhammer PF, Chodak G, Smith JA, Caplan R, et al. Prognostic factors in Stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen. Cancer 1993; 72: 1286-90.
  • 17
    Daniell HW. A worse prognosis for smokers with prostate cancer. J Urol 1995; 154: 153-7.
  • 18
    Daniell HW. A better prognosis for obese men with prostate cancer. J Urol 1996; 155: 220-5.
  • 19
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44.
  • 20
    Harman SM, Nankin HR. Alterations on reproductive and sexual function: male. In: AndresR, BiermanEL, HazzardWR, editors. Principals of geriatric medicine. New York: McGraw-Hill, 1985: 337-53.
  • 21
    Cotran RS, Kumar V, Robbins SL. Robbins pathologic basis of disease. Philadelphia: W.B. Saunders Company, 1989: 1104-5.
  • 22
    Fraass BA, Kinsella TJ, Harrington FS, Glatstein E. Peripheral dose to the testes: the design and clinical use of a practical and effective gonadal shield. Int J Radiat Oncol Biol Phys 1985; 11: 609-15.
  • 23
    Rannikko S, Kairento AL, Karonen SL, Adlercreutz H. Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumor, presence of metastases and grade of differentiation. Acta Endocrinol (Copenh) 1981; 98: 625-33.
  • 24
    Bartsch W, Steins P, Becker H. Hormone blood levels in patients with prostatic carcinoma and their relation to the type of carcinoma growth differentiation. Eur Urol 1977; 3: 47-52.